Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420524 · ClinicalTrials.gov registry record · Phase 1
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00420524 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT00420524, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment. The study population for this trial consists of patients with a documented advanced solid tumor. Patients will be stratified into 3 groups: those with normal liver function, and those with mild or moderate liver dysfunction.
Interventions
- DRUG Patupilone/EPO906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420524
The ClinicalTrials.gov registry entry for NCT00420524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patupilone/EPO906 is the first listed.
NCT00420524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420524 about?
NCT00420524 is a clinical study titled "A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function". This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment. The study population for this trial consists of patients with a documented advanced solid tumor. Patients will be stratified into 3 ...
What is the current status of trial NCT00420524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00420524?
The interventions under investigation include: Patupilone/EPO906 (DRUG).
Who is sponsoring clinical trial NCT00420524?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.